ProQR Therapeutics N.V.
PRQR
$1.94
$0.052.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.36M | 20.43M | 19.38M | 16.64M | 11.17M |
| Total Other Revenue | 698.20K | 692.60K | 547.60K | 395.90K | 269.40K |
| Total Revenue | 21.06M | 21.13M | 19.93M | 17.04M | 11.44M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 21.06M | 21.13M | 19.93M | 17.04M | 11.44M |
| SG&A Expenses | 14.43M | 14.77M | 15.71M | 15.71M | 16.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.64M | 54.09M | 52.05M | 47.63M | 47.74M |
| Operating Income | -35.59M | -32.97M | -32.13M | -30.59M | -36.30M |
| Income Before Tax | -32.55M | -30.26M | -26.23M | -23.26M | -28.88M |
| Income Tax Expenses | -215.30K | -212.00K | -206.60K | -251.20K | -81.60K |
| Earnings from Continuing Operations | -32.34 | -30.04 | -26.03 | -23.01 | -28.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 0.00 | -315.60K | -333.00K |
| Net Income | -32.34M | -30.04M | -26.03M | -23.33M | -29.13M |
| EBIT | -35.59M | -32.97M | -32.13M | -30.59M | -36.30M |
| EBITDA | -33.11M | -30.46M | -29.67M | -28.19M | -34.03M |
| EPS Basic | -0.35 | -0.35 | -0.32 | -0.29 | -0.36 |
| Normalized Basic EPS | -0.22 | -0.22 | -0.23 | -0.22 | -0.26 |
| EPS Diluted | -0.35 | -0.35 | -0.32 | -0.29 | -0.36 |
| Normalized Diluted EPS | -0.22 | -0.22 | -0.23 | -0.22 | -0.26 |
| Average Basic Shares Outstanding | 368.07M | 344.35M | 326.14M | 325.45M | 324.73M |
| Average Diluted Shares Outstanding | 368.07M | 344.35M | 326.14M | 325.45M | 324.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |